… independent of sex, preexisting cardiovascular disease, and COPD severity. To the best of
our knowledge, this study is the first to compare the cardiovascular safety of LABAs and LAAs …

… of the change in St’ George Respiratory Questionnaire (SGRQ), and cardiovascular
safety profile via the assessment of the risk of cardiovascular serious adverse events (SAEs). …

… known regarding the CV and cerebrovascular safety of LAMA/LABA combination therapy
from RCTs … post-authorization safety study of a LAMA/LABA combination therapy (umeclidinium/…

… The data on the CV safety of QVA149 are particularly reassuring, but are certainly not … the
therapeutic dose for causing cardiac pharmacodynamic effects showed a good CV safety and …

… the cardiovascular safety of dual bronchodilation therapy in … characterized by an acceptable
cardiovascular safety profile, at … bronchodilation therapy in inducing potential cardiovascular …

… This manuscript reviews the link between COPD, bronchodilators and cardiovascular
mortality. The roles of supplemental oxygen and corticosteroids have not been included in this …

… , 18 the use of oral theophylline in conjunction with albuterol, 19 or in the presence of
hypokalemia induced by nebulized bronchodilator therapy. The evaluation of safety data from …

… , cardiac myocyte growth and cardiac toxicity.[1] Peripherally, stimulation results in bronchodilation
… , such as salbutamol (albuterol) and salmeterol, are used as bronchodilators in the …

… The aforementioned 2015 meta-analysis revealed no significant differences in cardiovascular
safety profile between combination therapy with LAMA plus LABA and monotherapy [22]. …

… the contradictory findings in the literature, as well as recommended future research directions
to clear the air regarding the cardiovascular safety of inhaled long-acting bronchodilators. …